CARDIOVASCULAR
hamburger

Listen, download and subscribe to our podcast channel

Episode #1:

Advancing Heart Failure Care with LVAD Technology

Dr. Phil Adamson interviews Dr. Douglas Horstmanshof
January 13, 2021

With heart transplantation still considered the gold standard, what happens to a patient in advanced stages of heart failure when there just aren’t enough hearts to meet the demand? Driven by the success of the HeartMate 3™ LVAD, the field of Mechanical Circulatory Support (MCS) has advanced to a level where it is now being considered for more (indicated) patients. In this episode we discuss the latest in MCS, when advanced therapies should be considered and highlight the significance of a team approach, with Dr. Douglas Horstmanshof, Co-Director, INTEGRIS Advanced Cardiac Care.
 

Audience

Advanced Heart Failure Cardiologists

Speaker

Dr. Douglas Horstmanhof
Co-Director, INTEGRIS Advanced Cardiac Care, Oklahoma City, OK

Disclaimer: This podcast represents the views of our guest speaker and do not necessarily represent the views of Abbott. For more information regarding the products featured during this podcast please refer to the approved US indication, important safety information and instructions for use.

For more educational content on Abbott’s life-changing medical device technologies and resources, please visit cardiovascular.abbott

MAT-2100895 v1.0

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

False
accessibility
© 2019 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

accessibility

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.